Allist Pharmaceuticals

China

FollowEvery new trial, moved date and filing, and a Monday email
Furthest along
2 approved
1 in Phase 3
Next date
firmonertinib, Phase 3 trial completes
Drugs
4
in active trials · 5 in all
Trials
13 active
22 since 2021

Drugs4

DrugHow it worksPartnerStageNext dateDetails
EGFR inhibitor (third generation)
ArriVent BioPharma
Approved in China Dec 2026Phase 3 trial completes
—
Approved in China 31 Dec 2026Phase 2 trial completes
—
Phase 3 Mar 2027Phase 1/2 trial completes
—
Phase 1 Dec 2026Phase 1 trial completes

About

No active trial
Rifampicin
SEC filings
None: it does not file with the US SEC
Sources
ClinicalTrials.gov updated 16 Nov 2026 Industry-sponsored drug trials since 2021 · Logos provided by Logo.dev

Follow Allist Pharmaceuticals

Following is part of Solo: you see every change to Allist Pharmaceuticals the day it happens.

Solo

$49a month

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in